News for UroGen Pharma Ltd. (URGN)

NEW YORK, June 28, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of UroGen Pharma Ltd. (”œUroGen” or the ”œCompan

NEW YORK, June 23, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of UroGen Pharma Ltd. (”œUroGen” or the ”œCompan

PR NewswireNEW YORK, June 22, 2025 NEW YORK, June 22, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of UroGen Pharma Lt

NEW YORK, June 18, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of UroGen Pharma Ltd. (”œUroGen” or the ”œCompan

PR NewswireNEW YORK, June 17, 2025 NEW YORK, June 17, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of UroGen Pharma Lt

PR NewswireLOS ANGELES, June 16, 2025 LOS ANGELES, June 16, 2025 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, remind

U.S. stocks were higher, with the Dow Jones index gaining around 500 points on Monday. Shares of Sage Therapeutics, Inc. SAGE rose sharply during Monday's sess...

NEW YORK, June 16, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against UroGen Phar

NEW YORK, June 16, 2025 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP, a nationally acclaimed investor rights law firm, reminds UroGen Pharma Ltd. (”œUroGen”

UroGen Pharma (URGN) has been upgraded to a Buy rating from Neutral by H.C. Wainwright, with a price target set at $50. This change follows the announcement tha

U.S. stocks were lower, with the Dow Jones index falling around 600 points on Friday. Shares of Unusual Machines, Inc. UMAC rose sharply during Friday's sessio...

NEW YORK, June 08, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against UroGen Phar

LOS ANGELES, June 06, 2025 (GLOBE NEWSWIRE) -- The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shar

NEW YORK, June 04, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against UroGen Phar

NEW YORK, June 02, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against UroGen Phar

Leading securities law firm [url="]Bleichmar Fonti & Auld LLP[/url] announces that a lawsuit has been filed against UroGen Pharma Ltd. (NASDAQ: URGN) and certa

As May draws to a close, it's time to turn our attention to the FDA's upcoming slate of decisions. The following biotech companies are awaiting potential approvals in June 2025.

On May 23, 2025, Guggenheim's analyst Michael Schmidt released an update regarding the stock of UroGen Pharma (URGN). The analyst maintained a

Guggenheim has revised its price target for UroGen Pharma (URGN), bringing it down to $15 from the previous $40 while maintaining a Buy rating on the stock. The